Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma
- PMID: 1348796
- DOI: 10.1016/0140-6736(92)91528-g
Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma
Abstract
Aflatoxins have long been suspected to be human hepatic carcinogens but no direct study was feasible until assays to measure individual aflatoxin exposure became available. We have used assays for urinary aflatoxin B1, its metabolites AFP1 and AFM1, and DNA-adducts (AFB1-N7-Gua) to assess the relation between aflatoxin exposure and liver cancer, as part of an ongoing prospective study of 18,244 middle-aged men in Shanghai, People's Republic of China. After 35,299 person-years of follow-up, 22 cases of liver cancer had been identified. For each case, 5 or 10 controls were randomly selected from cohort members without liver cancer on the date the disorder was diagnosed in the case and matched to within 1 year for age, within 1 month for sample collection, and for neighbourhood of residence. Subjects with liver cancer were more likely than were controls to have detectable concentrations of any of the aflatoxin metabolites (relative risk 2.4, 95% confidence interval 1.0-5.9). The highest relative risk was for aflatoxin P1 (6.2, 1.8-21.5). In an analysis adjusting for the effects of hepatitis B surface antigen seropositivity, level of education, cigarette smoking, and alcohol consumption, the relative risk for the presence of aflatoxin metabolites was 3.8 (1.2-12.2). There was a strong interaction between serological markers of chronic hepatitis B infection and aflatoxin exposure in liver-cancer risk. Reduction of aflatoxin exposure may be a useful intermediate goal in prevention of liver cancer, since the benefits of wide-scale hepatitis B vaccination will not be apparent for many years.
Comment in
-
Aflatoxin biomarkers.Lancet. 1992 Jun 6;339(8806):1413-4. doi: 10.1016/0140-6736(92)91231-v. Lancet. 1992. PMID: 1350820 No abstract available.
Similar articles
-
A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China.Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):3-10. Cancer Epidemiol Biomarkers Prev. 1994. PMID: 8118382
-
Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan.Int J Cancer. 1996 Sep 4;67(5):620-5. doi: 10.1002/(SICI)1097-0215(19960904)67:5<620::AID-IJC5>3.0.CO;2-W. Int J Cancer. 1996. PMID: 8782648
-
Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan.J Hepatol. 1997 Aug;27(2):320-30. doi: 10.1016/s0168-8278(97)80178-x. J Hepatol. 1997. PMID: 9288607
-
Measurement of individual aflatoxin exposure among people having different risk to primary hepatocellular carcinoma.Princess Takamatsu Symp. 1985;16:225-35. Princess Takamatsu Symp. 1985. PMID: 3025163 Review.
-
Hepatocellular carcinoma: from gene to public health.J Natl Cancer Inst. 1997 Dec 17;89(24):1844-51. doi: 10.1093/jnci/89.24.1844. J Natl Cancer Inst. 1997. PMID: 9414172 Review.
Cited by
-
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.Clin Mol Hepatol. 2024 Jul;30(3):487-499. doi: 10.3350/cmh.2024.0145. Epub 2024 May 7. Clin Mol Hepatol. 2024. PMID: 38711390 Free PMC article.
-
Obesity is associated with biliary tract cancer mortality and incidence: A pooled analysis of 21 cohort studies in the Asia Cohort Consortium.Int J Cancer. 2024 Apr 1;154(7):1174-1190. doi: 10.1002/ijc.34794. Epub 2023 Nov 15. Int J Cancer. 2024. PMID: 37966009
-
Association of aflatoxin with gallbladder cancer in a case-control study nested within a Chinese cohort.Int J Cancer. 2024 Mar 1;154(5):801-806. doi: 10.1002/ijc.34755. Epub 2023 Oct 15. Int J Cancer. 2024. PMID: 37840351
-
Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians.Cancer Cell Int. 2023 Oct 13;23(1):239. doi: 10.1186/s12935-023-03092-5. Cancer Cell Int. 2023. PMID: 37833757 Free PMC article. Review.
-
Soluble CD137 and risk of hepatocellular carcinoma: nested case-control studies in cohorts in Shanghai and Singapore.Br J Cancer. 2023 Jun;128(11):2081-2088. doi: 10.1038/s41416-023-02223-z. Epub 2023 Mar 28. Br J Cancer. 2023. PMID: 36977826 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical